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Risk assessmentFuran is a chemical hepatocarcinogen in mice and rats. Its previously postulated cancer mode of action
(MOA) is chronic cytotoxicity followed by sustained regenerative proliferation; however, its molecular
basis is unknown. To this end, we conducted toxicogenomic analysis of B3C6F1 mouse livers following
three week exposures to non-carcinogenic (0, 1, 2 mg/kg bw) or carcinogenic (4 and 8 mg/kg bw) doses
of furan. We saw enrichment for pathways responsible for cytotoxicity: stress-activated protein kinase
(SAPK) and death receptor (DR5 and TNF-alpha) signaling, and proliferation: extracellular signal-regulated
kinases (ERKs) and TNF-alpha. We also noted the involvement of NF-kappaB and c-Jun in response to furan,
which are genes that are known to be required for liver regeneration. Furan metabolism by CYP2E1 pro-
duces cis-2-butene-1,4-dial (BDA), which is required for ensuing cytotoxicity and oxidative stress. NRF2
is a master regulator of gene expression during oxidative stress and we suggest that chronic NFR2 activity
and chronic inﬂammation may represent critical transition events between the adaptive (regeneration)
and adverse (cancer) outcomes. Another objective of this study was to demonstrate the applicability of
toxicogenomics data in quantitative risk assessment. We modeled benchmark doses for our transcriptional
data and previously published cancer data, and observed consistency between the two. Margin of exposure
values for both transcriptional and cancer endpoints were also similar. In conclusion, using furan as a case
study we have demonstrated the value of toxicogenomics data in elucidating dose-dependent MOA transi-
tions and in quantitative risk assessment.
Crown Copyright © 2013 Published by Elsevier Inc. Open access under CC BY license.rotein 1; ASK1, Apoptosis signal-
limit of benchmark dose; BrdU,
minal kinase 1; CT, Carbon tetra-
P450 2E1; EtOH, Ethanol; ERK,
ogy; GSH, Glutathione; HCA,
PA, Ingenuity Pathway Analysis;
ional Agency for Research on
tivated protein kinase; MPT,
tion; NTP, National Toxicology
uclear factor (erythroid-derived
; ROS, Reactive oxygen species;
factor; TNFR1, TNF receptor 1.
ce and Research Bureau, ERHSD,
03A), 50 Columbine Driveway,
.
ckson),
.com (L. Recio),
n.ca (I.B. Lambert),
r Inc. Open access under CC BY licenseIntroduction
Furan is a liver toxicant and rodent hepatocarcinogen that is classi-
ﬁed as possibly carcinogenic to humans (group 2B) by the International
Agency for Research on Cancer (IARC, 1995). Furanwas ﬁrst reported in
foods over 30 years ago (Maga andKatz, 1979). It is formed duringheat-
treatment of food, probably through thermal decomposition of carbohy-
drates, and is commonly found in coffee and canned and jarred foods
(including baby food) (Moro et al., 2012). It is also produced during
combustion and is therefore found in engine exhaust, wood smoke
and tobacco smoke (IARC, 1995). The National Toxicology Program's
(NTP) two-year cancer bioassay showed that furan induces hepatocel-
lular carcinoma (HCC) and adenoma (HCA) in a dose-dependent
manner in B6C3F1mice and HCC, HCA, cholangiocarcinoma, andmono-
nuclear cell leukemia in F344 rats (NTP, 1993); however, due to mixed
results in the standard battery of genotoxicity tests, furan's carcinogenic
mode of action (MOA)was ambiguous. Brieﬂy, at the time of the assess-
ment the available data on furan indicated that it is negative in theAmes
assay (±S9) but positive in the L5178Y/TK+/−mouse lymphoma assay.
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Chinese hamster ovary (CHO) cells (±S9) but not in vivo in B6C3F1
mouse bonemarrow cells. Finally, furan exposure induces chromosom-
al aberrations in both CHO cells (±S9) and B6C3F1mouse bonemarrow
cells (NTP, 1993). Subsequent studies to clarify the genotoxicity of
furan revealed that furan is not clastogenic, but that its metabolite
(cis-2-butene-1,4-dial (BDA)) causes strand breaks in L5178Y tk+/−
mouse lymphoma cells at high (often cytotoxic) doses (Kellert et al.,
2008). The results of in vivo MN assays for furan in mouse and rat are
typically negative (Durling et al., 2007; Leopardi et al., 2010; McDaniel
et al., 2012). While some researchers caution against the dismissal of a
genotoxicMOA for furan (Cordelli et al., 2010;Neuwirth et al., 2012), re-
cent studies using male transgenic Big Blue® rats (McDaniel et al.,
2012), and follow-up studies using the comet and micronucleus assays
inmale F344 rats (Ding et al., 2012) concluded that any genotoxic action
by furan is likely to be a secondary consequence of oxidative stress pro-
duced during furan metabolism.
The MOA proposed for furan based on apical (phenotypic) data de-
rived from female B6C3F1 mice (Fransson-Steen et al., 1997; Moser
et al., 2009) (supported by a weight of evidence from furan studies con-
ducted in other rodent models) is chronic cytotoxicity and inﬂamma-
tion followed by dysregulated regenerative proliferation, which is also
the most common MOA for spontaneous HCC (Nakagawa and Maeda,
2012). Indeed, in the NTP's 13-week study, dose-dependent increases
of histopathological markers for cytotoxicity, necrosis and cellular pro-
liferation were observed in B6C3F1 mice and F344 rats (both genders)
and, in the two-year study, therewas evidence of chronic inﬂammation,
hepatic ﬁbrosis, hyperplasia, degeneration and necrosis in the liver.
After two years the NTP researchers reported increased hepatic cancer
rates in both B6C3F1 mice and F344 rats (both genders), with a higher
sensitivity to furan in rats. Female mice had high hepatic cancer rates
at both doses tested (34/50 and 50/50 at 8 and 15 mg/kg bw, respec-
tively) and had a much lower spontaneous cancer rate than the
correspondingmalemice (26/50 and 7/50 inmales and females, respec-
tively). Moser et al. (2009) exposed female B6C3F1mice to lower doses
of furan (0, 0.5, 1, 2, 4 or 8 mg/kg bw) for three weeks or two years. In
their three week study they observed a signiﬁcant and dose-dependent
increase in hepatic cytotoxicity beginning at 1 mg/kg bw (measured by
serum alanine aminotransferase, ALT) and a signiﬁcant increase in
hepatocyte proliferation in the 8 mg/kg bw group (measured by
bromodeoxyuridine, BrdU, incorporation). They observed tumorigene-
sis at 4 and 8 mg/kg bw after two years. This study suggests that furan's
point of departure (POD) for carcinogenicity in female B6C3F1mice lies
between 2 and 4 mg/kg bw. Furan's no-observed adverse effect level
(NOAEL) in B6C3F1 mice and F344 rats (males and females) has been
reported as 0.12 mg/kg bw and 0.03 mg/kg bw, respectively (Gill
et al., 2010, 2011). Ultimately, apical studies in both genders of mice
and rats support the concept that furan causes cancer via a cytotoxicity
and regenerative proliferation MOA.
The ability of furan to induce levels of cytotoxicity sufﬁcient to pro-
mote regenerative proliferation is related to the chemical's metabolism.
Furan is metabolized into an electrophilic metabolite (BDA) by cyto-
chrome P450 2E1 (CYP2E1) (Kedderis and Held, 1996), which is the
only cytochrome P450 whose expression is not receptor-mediated. In-
stead, CYP2E1 is constitutively expressed and its activity is induced
post-transcriptionally by stabilization in the presence of its substrate.
Low molecular weight ligands, including ethanol (EtOH), acetamino-
phen (APAP), carbon tetrachloride (CT), chloroform and furan, increase
Cyp2E1's half-life from seven to 32 h (Gonzalez, 2007). In vitro experi-
ments have demonstrated that metabolic activation to BDA is necessary
for furan-induced cytotoxicity (Kellert et al., 2008), and inhibition of
CYP2E1 is sufﬁcient to prevent cytotoxicity in female B6C3F1 mice and
in mouse, rat or human microsomes (Fransson-Steen et al., 1997;
Gates et al., 2012). The CYP2E1 catalytic cycle produces reactive oxygen
species (ROS) (Gonzalez, 2005; Lu and Cederbaum, 2008) and BDA has
been shown to deplete cellular glutathione (GSH) levels in F344 rathepatocytes (Carfagna et al., 1993). There is evidence of oxidative
stress-induced genomic damage in response to furan exposure includ-
ing 8-oxo-dG adducts (Hickling et al., 2010) and oxidized purine and
pyrimidine bases (Ding et al., 2012) in rat liver. However, it is unclear
whether the indirect consequences of genotoxicity mediated via ROS
contribute to the MOA of furan.
Established assays for the identiﬁcation of non-genotoxic carcino-
gens are a current gap in the standard battery of short-term carcinoge-
nicity tests. Toxicogenomics is the study of changes in gene expression
following chemical exposure; induced perturbations in gene expression
are related to theMOAof carcinogens. Thus, toxicogenomics is expected
to provide an effective tool for the identiﬁcation of diverse MOAs and
may ﬁll an important testing gap for non-genotoxic carcinogens
(Waters et al., 2010). MOA information gleaned from toxicogenomic
studies of carcinogens has the added beneﬁt of providing mechanistic
information, thereby facilitating inter-species comparisons for inferring
human risk. In this study we characterize global gene expression
proﬁles in liver tissue taken from female B6C3F1 mice that were sub-
chronically exposed to non-carcinogenic (0, 1, 2 mg/kg bw) and carci-
nogenic (4 and 8 mg/kg bw) doses of furan. We perform extensive
bioinformatics analyses that are anchored in previously published apical
(phenotypic) endpoint data (Gill et al., 2011; Moser et al., 2009; NTP,
1993) in order to elucidate the molecular mechanism by which furan
causes liver cancer. More broadly, our goal is to use furan as a case
study to champion the concept of using sub-chronic exposures and ge-
nomic tools to inform risk assessment of non-genotoxic carcinogens.
Methods
Chemical
Furan (CAS no. 110-00-9) (N99% pure) (Sigma-Aldrich Chemical Co.,
Milwaukee,WI)wasmixedwithMazola corn oil to the appropriate con-
centration. Doses were prepared separately on a volume-to-weight
ratio (v:w), were de-aerated with inert gas, and were stored in 8 mL
brown glass vials (sealed with plastic closures and modiﬁed silicon
septa) in the refrigerator for up to 14 days (based on previous reports
of furan stability (NTP, 1993)).
Animals
5–6 week old female speciﬁc pathogen free B6C3F1 mice were pur-
chased from Charles River Breeding Laboratories (Portage, ME) and
were allowed to acclimatize for at least 7 days prior to the start of the
study. Feed (NIH-07; Zeigler Brothers, Inc., Gardners, PA) and tap
water were available ad libitum up until the time of necropsy. Mice
were housed ﬁve per cage in polycarbonate cages in a speciﬁc pathogen
free (SPF) and Association for Assessment and Accreditation of Labora-
tory Animal Care (AAALAC) accredited facility. All procedureswere con-
ducted in compliance with the Animal Welfare Act Regulations
(9CFR1–4). Mice were handled and treated according to the guidelines
provided in the National Institutes of Health (NIH) Guide for the Care
and Use of Laboratory Animals (ILAR, 1996; http://dels.nas.edu/ilar/).
Female mice were dosed with furan in corn oil at 0, 1, 2, 4, or
8 mg/kg bw per day by oral gavage for three weeks (n = 10 per
dose). We chose to use female mice because they have a lower spon-
taneous tumor rate than males (Haseman et al., 1998). n = 4, 5, 3, 4,
or 5 per dose group were treated with 0.02% Bromodeoxyuridine
(BrdU; Sigma Chemical Co., St. Louis, MO, USA) in drinking water
for 5 days just prior to sacriﬁce. Upon necropsy, there remained
n = 5 mice in each non-BrdU group. Some mice were lost due to
early (pre-BrdU treatment) mis-dosing or esophageal puncture.
Four hours after their ﬁnal dosing, mice were anesthetized by CO2
inhalation prior to euthanasia by exsanguination achieved by cutting
the caudal vena cava after blood collection. One animal per group
was killed and this continued until all mice had been sacriﬁced;
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weights were recorded. Serum enzymes were not analyzed since
these endpoints have been previously examined and reported (Gill
et al., 2011; Moser et al., 2009; NTP, 1993). The left, median, right
posterior and right anterior lobes of the liver were cut into 3 sec-
tions. One section from each lobe was cut into 0.25–0.5 cm3 pieces.
These were snap-frozen in liquid nitrogen then stored at or below
−70 °C until processed for RNA extraction. The remaining two sec-
tions of liver were ﬁxed for 18 h or three weeks in neutral
phosphate-buffered formalin, then in 100% ethanol for 72 h and
stored (for use in studies to be published separately).Immunohistochemistry for BrdU nuclear staining
Hepatocytes undergoing DNA synthesis were identiﬁed by BrdU nu-
clear staining using immunohistochemistry. Brieﬂy, liver sections were
stained for BrdU in an automatic stainingmachine (IntelliPATH, Biocare,
Concord, CA). A small section of duodenumwas evaluated on each slide
as a positive control to ensure adequate BrdU delivery and staining.
Deparafﬁnized sections were incubated with hydrochloric acid for
20 min at 37 °C for antigen retrieval, neutralized in borate buffer, and
immersed in trypsin for 3 min at 37 °C for antigen retrieval. The sec-
tions were exposed to 10% normal rabbit serum for 20 min at room
temperature to inhibit nonspeciﬁc binding. The sections were then
incubated for 1 h at room temperature with rabbit monoclonal anti-
BrdU antibodies (Accurate Chemical and Scientiﬁc Corporation,
Westbury, NY) diluted 1:1000. Sections were incubated with hydrogen
peroxide for 15 min followed by incubation with avidin and biotin
(Vector, Burlingame, CA) at room temperature for 15 min each. After-
wards the sections were incubated with rabbit anti-rat IgG (Vector,
Burlingame, CA) at a 1:500 dilution for 30 min at room temperature
to capture primary antibody. Sections were then incubated with Vector
ABC label for 30 min at room temperature. The antigen–antibody reac-
tion was visualized with betazoid diaminobenzidine (Biocare, Concord,
CA) for 5 min. The sections were counterstained with CAT hematoxylin
(Biocare, Concord, CA) for 2 min.
A liver section from each mouse was microscopically evaluated for
hepatocyte cell proliferation. Random ﬁelds in the liver were scored
without knowledge of animal identity for BrdU incorporation by light
microscopy. At least 1000 cells per slide were counted. The percent la-
beling index was calculated by the total number of immunoreactive
BrdU labeled hepatic nuclei divided by the total number of nuclei count-
ed times 100. Representative images from each dose group were cap-
tured on an Olympus BX41 microscope and Olympus DP25 camera.
A generalized linearmodelwas applied to thedatawith thebinomial
error distribution using the R software (R-Development-Core-Team,
2010). The glht function in the multcomp library (Hothorn et al.,
2008) for testing general linear hypotheses was used to test for differ-
ences between exposed and controls. The P-values from Wald's test
were adjusted using the Dunnett's multiple comparison procedure
(Dunnett, 1955). Estimates were back-transformed to obtain fold
change estimates and the delta method was applied to obtain the
estimate for the standard errors.RNA extraction
RNA was extracted from ~100 mg frozen liver tissue using the
RNeasy Midi RNA Extraction kit (Qiagen, Mississauga, ON, Canada). An
Omni tissue homogenizer with a disposable 7 mm Omni generator
probe was used (Omni #34750, Omni International, Marietta, GA).
RNA was quantiﬁed using a NanoDrop Spectrophotometer (Thermo
Fisher Scientiﬁc Inc., Wilmington, DE, USA) and qualiﬁed using an
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Mississauga, ON,
Canada) and stored at−80 °C.Microarray
RNA was extracted from each of the non-BrdU mice for all furan
doses (0, 1, 2, 4, 8 mg/kg bw; n = 5 per dose group). Sample RNA
(200 ng) was used together with a mouse universal reference RNA
(Stratagene by Agilent Technologies Inc., Mississauga, ON, Canada) to
synthesize, amplify and label cRNA using the Low Input Quick Amp La-
beling Kit (Agilent Technologies Inc., Mississauga, ON, Canada). Labeled
cRNAwas puriﬁed using the RNeasy Mini Kit (Qiagen, Mississauga, ON,
Canada). Ampliﬁcation and labeling efﬁciency of cRNA were quantiﬁed
using a NanoDrop spectrophotometer. Hybridization mixes were pre-
pared using the Hi-RPM Gene Expression Hybridization Kit (Agilent
Technologies Inc., Mississauga, ON, Canada). 300 ng of Cy3-labeled ref-
erence RNA and 300 ng Cy5-labeled sample cRNA were hybridized on
SurePrint G3 Mouse GE 8 × 60 K microarrays (Agilent Technologies
Inc., Mississauga, ON, Canada) at 65 °C for 17 h at 10 rpm. Slides were
washed according to the manufacturer's speciﬁcations with Gene Ex-
pression Wash Buffers 1 and 2 (Agilent Technologies Inc., Mississauga,
ON, Canada), scanned using an Agilent G2505B scanner at 5 μm resolu-
tion. Data were extracted using Agilent Feature Extraction Software,
version 11. The complete dataset is available through the Gene Expres-
sion Omnibus (http://www.ncbi.nlm.nih.gov/geo/) accession number
GSE48644.
A block design, treating the slide as the blocking effect was
employed to determine global differential gene expression. Median sig-
nal intensitieswere normalized using LOWESS (Bolstad et al., 2003) in R
(R-Development-Core-Team, 2010). Probes with technical replicates
were then averaged. Differential gene expression was determined
using the microarray analysis of variance (MAANOVA) library (Wu
et al., 2003). The Fs statistic (Cui et al., 2005), a shrinkage estimator,
was used to determine gene-speciﬁc treatment effects, and the associat-
ed P values were estimated using the permutationmethod (30,000 per-
mutations with residual shufﬂing). The P-values were adjusted for
multiple comparisons using the false discovery rate (FDR) approach
(Benjamini and Hochberg, 1995). Fold changes were estimated using
least square means of each pairwise comparison. Genes having an
FDR-adjusted P ≤ 0.05 and a fold change ≥±1.5 were deemed differ-
entially expressed. Upon removal of outliers (arrays with high back-
ground), the ﬁnal sample sizes used for gene expression analysis were
n = 5, 4, 5, 4, and 5 for 0, 1, 2, 4, and 8 mg/kg bw furan dose groups,
respectively.
Bioinformatics
Ingenuity Pathway Analysis (IPA). IPA (http://www.ingenuity.com/
products/ipa) was used to identify molecular pathways that were af-
fected by furan treatment and to predict activated upstream regulators.
The expression and signiﬁcance cut-offs applied to the data were fold
change ≥±1.5 and FDR-adjusted P ≤ 0.05. Enrichment of a canonical
pathway is determined in IPA based on the number of differentially
expressed genes in the data set that also appear in the pathway. The sig-
niﬁcance threshold for canonical pathways is P ≤ 0.05where P is calcu-
lated using a right-tailed Fisher's exact test by IPA. Signiﬁcance of
predicted upstream regulators was calculated by IPA and quantiﬁed
using a Z-score (we considered Z N 1.9 as activated and Z b −1.9 as
inhibited), which takes into account the number of downsteam genes
that are differentially expressed in the gene list.
Disease prediction and chemical proﬁle comparison. Gene expression
changes induced by 8 mg/kg bw furanweremined against public geno-
mic data repositories for chemical- and disease-induced changes in
gene expression using NextBio (http://nextbio.com). Pairwise gene sig-
nature correlations and rank-based enrichment statistics are employed
in the NextBio score calculations, where the chemical or disease with
the highest similarity will be given a score of 100 and the rest are
being normalized accordingly (Kupershmidt et al., 2010).
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Principle component analysis was conducted on the relative signal
intensities for the signiﬁcant probes based on the correlation matrix in
R using the prcomp() function (Becker et al., 1998; Mardia et al.,
1979; Venables and Ripley, 1999). The ﬁrst three components were
then plotted using the scatterplot3d() function in the scatterplot3d li-
brary (Ligges and Mächler, 2003).
Cluster analysis
Data was obtained from Gene Expression Ominibus (http://www.
ncbi.nlm.nih.gov/geo/) and European Bioinformatics Institute (http://
www.ebi.ac.uk/arrayexpress/). All data sets that used the Affymetrix
platform (E-MEXP-82; GSE13149; GSE18858; GSE20427; GSE26538)
were normalized using Robust Multi-array Average, RMA (Irizarry
et al., 2003), using the ReadAffy() function in the affy library in R
(Gautier et al., 2004). Two-color platform (Furan; BaP) background
subtracted signal intensities were normalized using the LOWESS ap-
proach and background subtracted signal intensities for GSE35934 and
GSE4874 (with a dye adjustment) were normalized using cyclic
LOWESS (Bolstad et al., 2003).
Normalized probe intensities with common Gene Symbols were
then collapsed using the median normalized signal intensity. Based on
Gene Symbol, all normalized data were merged together yielding
3190 common Gene Symbols. A heatmap using these data was pro-
duced using 1-Pearson correlation as the distance metric with average
linkage.
Benchmark dose (BMD) calculations
Apical endpoint data. BMD and BMDL (lower conﬁdence limit of BMD)
values were modeled for previously reported apical endpoint measure-
ments (Gill et al., 2011;NTP, 1993) using theUnited States Environmental
Protection Agency's (US EPA) Benchmark Dose Software (BMDS) version
2.3.1 (http://www.epa.gov/ncea/bmds/) (Davis et al., 2011). Data were
pre-screened for homogeneity of variance. Continuous data were run
against ﬁve models (Exponential, Hill, Linear, Polynomial and Power)
and dichotomous data were run against nine models (Gamma Multi, Lo-
gistic, LogLogistic, LogProbit, Multistage, Multistage Cancer, Probit,
Weibull and Quantal-Linear). The best model for each data set was
chosen based on visual inspection of curve ﬁtting, lowest Akaike's Infor-
mation Criterion (AIC, which measures the relative goodness of ﬁt)
value, goodness of ﬁt P N 0.05, and scaled residuals between +2.0 and
−2.0. The AIC was used as the deciding factor between equally well
ﬁttingmodels. These selection criteriawere appliedwhen values generat-
ed from eachmodel were within 3-fold of each other, otherwise the low-
est value was used.
Gene expression data. BMDExpress (Yang et al., 2007) was applied to
calculate BMD (mean and median) and BMDL (mean and median)
values for genes, IPA pathways and GO terms. Datasets were pre-
ﬁlteredwith FDRP ≤ 0.05 and fold change ≥ 1.5 in at least onedose be-
fore importing into BMDExpress. Five models were compared (Hill,
Power, Linear, Polynomial 2° and Polynomial 3°) and the best was cho-
sen based on: (1) a nested Chi-square test, with cut-off of 0.05; (2) the
lowest AIC; (3)maximum iterations of 250; (4) conﬁdence level of 0.95;
and (5) benchmark response (BMR) of 1.349 (number of standard devi-
ation deﬁning BMD), which corresponds to an excess risk of 10%. The
power model had a power restriction of ≥1. Selection of Linear and
Polynomial 2° was based on choosing a model that describes the data
with the least complexity. A Hill model was excluded if the “k” parame-
ter of the model was less than 1/3 of the lowest positive dose as per
Black et al. (2012). The datasets were mapped to Ingenuity Core Path-
ways (http://www.ingenuity.com) using theDeﬁned Category Analyses
feature. The pathway dataset was downloaded from Ingenuity PathwayAnalysis (December 13, 2012) and array annotation dataset, MM_
WG_GPL10333, was downloaded from NCBI Gene Expression Omnibus
(October 18, 2011 version).
Margin of exposure
Margin of exposure (MoE) is ametric used to infer public health risk.
Typically a MoE of 10,000 or greater indicates that a compound is not a
public health concern (Benford et al., 2010; EFSA, 2005); however 1000
is the benchmark used for furan since it is a relativelywell characterized
chemical and therefore has a lower uncertainty factor associated with it
(IRIS, 2012). In this studyMoEswere calculated by dividing the relevant
BMDL (μg/kg bw) by the actual environmental exposure (μg/kg-bw/
day). Average (50th percentile) and high (90th percentile) environ-
mental exposure estimates for USA or Europe, and for infants or com-
bined child/adult populations were taken from Carthew et al. (2010).
Apical MoEswere calculated for HCC andHCA, with tumor BMDL values
calculated using cancer rates published by Moser et al. (2009) and NTP
(1993). Transcriptional MoEs were calculated for the NRF2 Oxidative
Stress Response IPA pathway and for a ‘General transcriptional re-
sponse,’ the latter was calculated using the average BMDL for all
enriched pathways with at least ﬁve molecules and P b 0.05. We use
the BMDL value obtained from the best model (as described above)
for MoE calculations.
Results
Cellular proliferation (BrdU), cytotoxicity and cancer
Treatment-related effects of 0, 1, 2, 4, or 8 mg/kg bw furan for three
weeks on mice (including measurement of serum enzymes and histo-
pathological markers of cytotoxicity and inﬂammation) have been
previously reported (Gill et al., 2011; Moser et al., 2009; NTP, 1993)
and therefore were not repeated in this study. Body weight was not af-
fected by furan exposure (Suppl. Table S1). BrdU incorporation was ob-
served to increase with increasing furan dose. Labeling indices for BrdU
of 2.3, 2.4, 2.9, 5.2, and 7.6% at 0, 1, 2, 4 and 8 mg/kg bw furan, respec-
tively, were observed, with a signiﬁcant increase in BrdU incorporation
at 8 mg/kg bw (P = 0.00413) (Fig. 1a). Similar results for BrdU incor-
poration were previously reported in Moser et al. (2009).
Previous studies have reported increases in cytotoxicity and prolifer-
ative histopathological markers (Gill et al., 2011; Moser et al., 2009;
NTP, 1993) as well as cancer rates (Moser et al., 2009; NTP, 1993) in re-
sponse to furan. Wemodeled dose responses for these apical endpoints
and our own BrdU incorporation data using BMDS (Table 1) and ob-
served that BMD/BMDL variability between studies was low for cancer
endpoints, but was quite large for cytotoxicity and proliferation
markers.
Gene expression analysis
Following furan treatment, the number of differentially expressed
genes increased in a dose-dependent manner with 2, 17, 27 and 339
genes (2, 18, 43 and441probes) in the1, 2, 4, or 8 mg/kg bwdose groups,
respectively (Fig. 1b). While fold changes ranging between +20.65 and
−6.60 were observed, the majority of signiﬁcantly changed probes had
fold changes of ±1.5–2.0. There was a complete overlap between the dif-
ferentially expressed genes in the 4 and 8 mg/kg bw dose groups, and
only one shared gene between the 2 and 4 mg/kg dose groups thus indi-
cating a clean transition in the nature of the transcriptional response. A
PCA analysis revealed a dose-related clustering of hepatic expression pro-
ﬁles (Fig. 1c).We sawup-regulation of a number of genes consistentwith
our proposed MOA for furan including genes involved in oxidative stress
response, xenobiotic metabolism, inﬂammation, cell cycle arrest/cell
death and cell survival and growth (Table 2; Suppl. Table S2). Using
BMDExpress, we calculated median BMD/BMDL values for individual
050
100
150
200
250
300
350
400
1.0 2.0 4.0 8.0
N
um
be
r o
f d
iff
er
en
tia
lly
 e
xp
re
ss
ed
 g
en
es
Furan dose (mg/kg bw)
0
2
4
6
8
10
12
0.0 1.0 2.0 4.0 8.0
B
rd
U 
Po
si
tiv
e 
(%
)
Furan dose (mg/kg bw)
*
ba
c
Fig. 1.Dose response due to furan. (a) Dose-dependent increase in liver cell proliferation upon exposure to furan based upon BrdU incorporation (+/−stdev; *P = 0.00413). (b) Number
of furan-responsive differentially expressed genes in eachdose group andVenndiagrams represent the overlap of individual furan-responsive genes in eachdose group. (C) Principal com-
ponent analysis (PCA) of furan dose groups,where circles represent individualmice and colors indicated dose groups (royal blue, 8 mg/kg bw; green, 4 mg/kg bw; pink, 2 mg/kg bw; red,
1 mg/kg bw; aqua blue, 0 mg/kg bw).
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be important for the furanMOAwere close to the 2–4 mg/kg transitional
dose range, and this trend persisted regardless of the magnitude of the
fold change of the probes used in the modeling (Table 2, Suppl. Table S3).
Cluster analysis
Cluster analysis was performed using gene lists from 1, 2, 4 and
8 mg/kg bw furan dose groups and gene expression data sets from
GEO (http://www.ncbi.nlm.nih.gov/geo/) from spontaneous hepatocel-
lular carcinoma, liver regeneration following partial hepatectomy, liver
inﬂammation, and chemical exposure to hepatocarcinogens, non-
hepatocarcinogens and Cyp2E1 ligands (APAP and CT) (Fig. 2, Suppl.
Table S4). Furan dose groups clustered closely together, with a split
between the lower dose groups and the 8 mg/kg dose group. The
8 mg/kg bw furan dose group clustered most closely with a hepatocel-
lular carcinoma (HCC) data set, followed by liver regeneration 38 and
48 h post-PH. The 1, 2 and 4 mg/kg furan dose groups clustered with
a dataset representing NF-kappaB-mediated liver inﬂammation. These
cluster together with a large group of hepatocarcinogens and a small
group of Cyp2E1 substrates.
Pathways and upstream regulators of transcription analyses
Pathway analysis (using IPA) was employed to provide informa-
tion regarding the furan molecular MOA. The number of enriched
pathways increased in a dose-dependent manner. There were no
enriched pathways at the lowest dose (1 mg/kg bw) and pathway
enrichment at the next two doses (2 and 4 mg/kg bw) was always
based on three or fewer genes, therefore we focused on pathwaysenriched at the highest dose (8 mg/kg bw). Pathways relevant to
the furan MOA included NRF2 Oxidative Stress Response, Glutathione
Metabolism, Xenobiotic Metabolism, Death Receptor Signaling, TNF-
alpha/ASK1/JNK1 Apoptosis Signaling (within the 14-3-3 Signaling
pathway), Erk/MAPK Signaling and Breast Cancer Regulation by
Stathmin1 (Fig. 3A). In addition, enrichment of the p53 Signaling
pathway indicated that the DNA damage response could be in-
volved. Other pathways, including the Xenobiotic Metabolism path-
way and the Aryl Hydrocarbon Receptor pathway, were also
enriched in response to furan. While the Xenobiotic Metabolism
pathway comprises CAR, PXR, AhR, PPAR and Nrf2 signaling, Nrf2
was the only one among these that was appreciably activated. Clos-
er inspection of the Aryl Hydrocarbon pathway showed that enrich-
ment of this pathway was almost exclusively the result of an
increase in the expression of the estrogen receptor (Esr1), and not
the AhR. These ﬁndings are consistent with previous studies
showing that furan does not undergo receptor-mediated metabo-
lism. BMD modeling for individual pathways demonstrated that
BMDL values fell around the 2–4 mg/kg transitional dose range
(Fig. 3A). For all IPA pathways (that could be modeled and that
had at least ﬁve genes with signiﬁcant changes in expression) the
average pathway BMDL mean was 2.20 mg/kg bw (range 1.50–
4.40 mg/kg bw).
Upstream regulators of transcription were predicted using IPA
software. There were no predicted upstream regulators for the 1 or
2 mg/kg bw dose groups. TNF-alpha was the only predicted upstream
regulator in the 4 mg/kg bw dose group. There were many predicted
upstream regulators for the 8 mg/kg dose group; in particular, activation
of reactive oxygen species, hydrogen peroxide, other Cyp2E1 ligands
(CT, APAP, EtOH), cytokines (including TNF-alpha), growth factors,
Table 1
BMDmodeling of previously published apical endpoint data for furan exposures in B6C3F1
mice. For cytotoxicity and proliferativemarkers Gill et al. (2011) exposedmale and female
mice to 0, 0.03, 0.12, 0.5, 2 and 8 mg/kg furan for 13 weeks and the NTP (1993) exposed
female mice to 0, 2, 4, 8, 15, 30 and 60 mg/kg bw furan for 13 weeks. For cancer studies,
Moser et al. (2009) exposed female mice 0, 0.5, 1, 2, 4 and 8 mg/kg bw furan for two
years and the NTP (1993) exposed female mice to 0, 8 and 15 mg/kg furan for two
years; cancer incidences in these studies are in brackets.
Apical endpoint BMD
(mg/kg bw)
BMDL
(mg/kg bw)
Cytotoxicity markers (Gill et al., 2011)
Serum alanine transaminase (ALT) 1.84 1.35
Hepatocyte apoptosis (caudate lobe) 0.43 0.11
Hepatocyte apoptosis (other lobes) 1.37 0.28
Kuffer cell pigmentation and inﬂammation 1.20 0.28
Cytotoxicity markers (NTP, 1993)
Hepatocyte degeneration 19.85 14.67
Hepatocyte necrosis 23.50 14.44
Kupffer cell pigmentation 23.50 14.44
Cholangioﬁbrosis 27.16 17.57
Proliferation markers (this study)
BrdU labeling index 1.10 0.67
Proliferation markers (Gill et al., 2011)
Hepatocyte basophilia 0.60 0.30
Biliary tract hyperplasia 5.81 1.05
Proliferation markers (NTP, 1993)
Biliary tract hyperplasia 24.58 14.54
Hepatocyte cytomegaly 19.85 14.67
Cancer (NTP, 1993)
Hepatocellular adenoma (5/50, 31/50, 48/50) 2.78 0.92
Hepatocellular carcinoma (2/50, 7/50, 27/50) 6.61 5.30
Hepatocellular adenoma or carcinoma
(7/50, 34/50, 50/50)
6.88 4.20
Cancer (Moser et al., 2009)
Hepatocellular adenoma
(3/36, 4/72, 4/53, 4/41, 11/36, 25/39)
2.34 1.34
Hepatocellular carcinoma
(0/36, 4/72, 2/53, 1/41, 2/36, 11/39)
2.60 1.57
Hepatocellular adenoma or carcinoma
(3/36, 8/72, 6/53, 5/41, 12/36, 29/39)
5.14 4.22
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transcription factors (including Nrf2 (Nfe2l2) and NF-κB1), and hor-
mones (including estrogen and thyroid hormone) were predicted
(Fig. 3A).
Disease and chemical prediction
Meta-analyses comparing the changes in gene expression observed
in the 8 mg/kg bw dose group to other gene expression studies were
conducted using theNextBioHumanDisease Atlas and revealed similar-
ities to the following: Injury to Liver (97.4), Liver Regeneration (91.7),
Hepatic Fibrosis (82.25), Hepatocellular Dysplasia (80.9), Liver Cancer
(73.0), Inﬂammatory Disease of the Liver (68.5), and Cirrhosis of the
Liver (52.07). In addition, using the NextBio Chemical Atlas, similarities
were observedwith chloroform (47.42), CT (43.02), hydrogen peroxide
(40.75), and APAP (39.12). Interestingly, 8 mg/kg bw furan was found
to produce gene expression changes thatweremost similar to the insec-
ticide malathion (100) (Suppl. Tables S5 and S6).
GO terms
There were many, redundant GO terms enriched for that were rele-
vant to furan's primary MOA. Interestingly, mean BMDL values
approached the expected ~2–4 mg/kg range, including: kinase activity(GO: 0016301; BMDL 1.89 mg/kg bw), regulation of transcription, DNA
dependent regulation of transcription (GO: 0006355; BMDL 2.14 mg/
kg bw), regulation of protein modiﬁcation process (GO: 0031399;
BMDL 1.90 mg/kg bw), regulation of apoptosis (GO: 0042981; BMDL
1.90 mg/kg bw), negative regulation of apoptosis (GO: 0043066; BMDL
2.18 mg/kg bw), and regulation of gene expression (GO: 0010468;
BMDL 2.04 mg/kg bw). One gentoxicity-relevant GO term, response to
DNA damage stimulus (GO: 0006974; BMDL 2.06 mg/kg bw), was also
enriched for (full list: Suppl. Table S7).
Margin of exposure (MoE)
Two MoEs each were calculated for apical (HCC and HCA) and
transcriptional (NRF2 Oxidative Stress Response pathway and General
Transcriptional Response) endpoints. Estimates of risk calculated for
apical or transcriptional endpoints were generally quite consistent
(Table 3).
Discussion
Global transcriptomic analyses on liver tissue collected from mice
exposed sub-chronically to non-carcinogenic (0, 1, 2 mg/kg bw) and
carcinogenic (4 and 8 mg/kg bw) doses of furan were carried out to
provide qualitative and quantitative mechanistic insight into how
furan causes liver cancer. The most commonMOA for the development
of liver cancer is chronic cytotoxicity and inﬂammation leading to re-
generative proliferation (Nakagawa and Maeda, 2012). This MOA is
also hypothesized to underlie carcinogenicity induced by other
chemicals including the group 2B non-genotoxic carcinogens CT
(Manibusan et al., 2007) and chloroform (Larson et al., 1994; Templin
et al., 1996). Furan is believed to cause cancer by this MOA (Fransson-
Steen et al., 1997; Moser et al., 2009); however, it is not clear how
furan stimulates this process on a molecular level. Our case study sup-
ports the hypothesis that furan's primary MOA is cytotoxicity followed
by cellular proliferation and regeneration. The analysis also supported
potential genotoxicity occurring at the high dose via indirect mecha-
nisms (i.e.: ROS generation). Our discussion focuses primarily on the
non-genotoxic MOA; an important outcome of this case study is the
demonstration that sub-chronic in vivo toxicogenomics studies can be
used to discern MOA information for non-genotoxic carcinogens, and
that these data can be used to informquantitative human health risk as-
sessment. This is an important ﬁnding because non-genotoxic carcino-
gens aren't detected by short-term mutagenicity tests, and the length
and cost of the two-year rodent bioassay is prohibitive.
In this study we observed an increase in cellular proliferation
after three weeks of furan exposure at both of the carcinogenic
doses examined (Fig. 1a), which conﬁrmed the induction of the
furan MOA and was consistent with previously published results
(Moser et al., 2009). Although no measurements for cytotoxicity
were taken in our study, this in vivo response to furan is well-
characterized elsewhere (Gill et al., 2011; Moser et al., 2009; NTP,
1993), as is the in vitro cytotoxicity of BDA (Kellert et al., 2008).
We also noted that all of the differentially expressed genes at
4 mg/kg bw were contained within the 8 mg/kg bw gene list and
were distinct from those observed at 2 mg/kg bw, indicating that a
shift from an adaptive/stress response to an adverse/cancer re-
sponse had presumably occurred (Fig. 1b). The molecular MOA of
the adverse response to furan was best characterized by relying on
the carcinogenic 8 mg/kg bw dose group, since it had the most pop-
ulated list of differentially expressed genes, it clustered with liver re-
generation and liver cancer datasets, and clustered separately from
the lower dose groups (Fig. 1c; Fig. 2). This separate clustering sug-
gests that the 8 mg/kg bw livers had progressed further toward the
HCC and HCA disease molecular phenotype during the three week
exposure than the (also carcinogenic) 4 mg/kg bw dose group. An-
other possibility is that the MOA at 4 mg/kg is different from that
Table 2
Genes that are differentially expressed (fold change N ±1.50; P b 0.05) in response to 8 mg/kg bw furan and relevant to the furanmode of action. BMD/BMDL values for individual genes
are listed (unless the software was unable to model the dose response of their gene expression, or the value exceeded 8 mg/kg).
Probe ID GenBank
accession
Gene symbol Gene name Fold change
(8 mg/kg furan)
BMD
(mg/kg bw)
BMDL
(mg/kg bw)
Oxidative stress response and xenobiotic metabolism
A_52_P664506 NM_018811 Abhd2 Abhydrolase domain containing 2 1.56 1.42
A_55_P2177233 NM_026179 Abhd5 Abhydrolase domain containing 5 1.61 2.16 1.65
A_52_P273821 NM_026179 Abhd5 Abhydrolase domain containing 5 1.68 1.38 0.70
A_55_P2163098 NM_134066 Akr1c18 Aldo-keto reductase family 1, member C18 2.78 4.37 3.00
A_55_P2154416 NM_030558 Car15 Carbonic anhydrase 15 2.10 2.05 1.57
A_51_P455647 NM_009801 Car2 Carbonic anhydrase 2 2.12 3.08 2.25
A_66_P108152 NM_007620 Cbr1 Carbonyl reductase 1 1.63 2.92 2.15
A_51_P481159 NM_173047 Cbr3 Carbonyl reductase 3 2.53 3.14 2.29
A_55_P2124712 NM_145603 Ces2 Carboxylesterase 2 3.08 2.68 2.00
A_52_P318361 NM_145603 Ces2 Carboxylesterase 2 3.62 2.72 2.02
A_51_P179919 NM_172759 Ces5 Carboxylesterase 5 1.91 7.36 4.51
A_55_P1954718 NM_007805 Cyb561 Cytochrome b-561 1.88
A_55_P2140107 NM_009995 Cyp21a1 Cytochrome P450, family 21, subfamily a, polypeptide 1 1.52
A_55_P2007326 NM_009997 Cyp2a4 Cytochrome P450, family 2, subfamily a, polypeptide 4 1.51
A_51_P137452 NM_013809 Cyp2g1 Cytochrome P450, family 2, subfamily g, polypeptide 1 −1.80 7.87 4.55
A_51_P482051 NM_007820 Cyp3a16 Cytochrome P450, family 3, subfamily a, polypeptide 16 1.60 1.05
A_55_P2001780 NM_001105159 Cyp3a41b Cytochrome P450, family 3, subfamily a, polypeptide 41B 1.67
A_52_P164161 NM_020010 Cyp51 Cytochrome P450, family 51 1.62 0.97 0.16
A_55_P2002577 NM_010145 Ephx1 Epoxide hydrolase 1, microsomal 1.70 2.79 2.07
A_55_P2002578 NM_010145 Ephx1 Epoxide hydrolase 1, microsomal 1.94 3.24 2.00
A_51_P365019 NM_010295 Gclc Glutamate-cysteine ligase, catalytic subunit 1.61 5.40 3.95
A_55_P2032946 NM_008181 Gsta1 Glutathione S-transferase, alpha 1 (Ya) 15.28 4.98 3.42
A_55_P2170454 NM_008182 Gsta2 Glutathione S-transferase, alpha 2 (Yc2) 3.63 3.25 1.70
A_55_P2062190 NM_010358 Gstm1 Glutathione S-transferase, mu 1 1.66 6.33 4.97
A_55_P1957038 NM_181796 Gstp2 Glutathione S-transferase, pi 2 1.56 7.74 5.79
A_51_P263965 NM_010442 Hmox1 Heme oxygenase (decycling) 1 2.09 7.61 4.20
A_55_P2029687 NM_010442 Hmox1 Heme oxygenase (decycling) 1 1.66 6.09 3.84
A_51_P424338 NM_008706 Nqo1 NAD(P)H dehydrogenase, quinone 1 1.71 3.08 2.25
A_51_P161354 NM_144907 Sesn2 Sestrin 2 1.80 2.63 1.97
A_51_P243755 NM_011388 Slc10a2 Solute carrier family 10, member 2 3.61 1.09
A_55_P1969506 NM_009198 Slc17a1 Solute carrier family 17 (sodium phosphate), member 1 1.52
A_52_P286520 NM_018824 Slc23a2 Solute carrier family 23 (nucleobase transporters), member 2 −1.52 4.61 3.13
A_55_P1964752 NM_194333 Slc23a3 Solute carrier family 23 (nucleobase transporters), member 3 2.27 2.55 1.91
A_51_P514405 NM_019741 Slc2a5 Solute carrier family 2 (facilitated glucose transporter), member 5 −1.92 4.88 3.27
A_52_P193194 NM_001001321 Slc35d2 Solute carrier family 35, member D2 1.66 7.84 4.66
A_55_P2033120 NM_029688 Srxn1 Sulﬁredoxin 1 homolog (Saccharomyces cerevisiae) 1.73 4.65 2.95
A_51_P353895 NM_026935 Sult1c2 Sulfotransferase family, cytosolic, 1C, member 2 −1.81 3.40 2.45
A_55_P2129449 NM_020565 Sult3a1 Sulfotransferase family 3A, member 1 −2.55 4.16 3.31
A_51_P320614 NM_001042523 Txnrd1 Thioredoxin reductase 1 1.52 1.76 0.66
A_55_P2006236 NM_009466 Ugdh UDP-glucose dehydrogenase 1.82 7.42 4.16
A_55_P2057577 NM_145079 Ugt1a6a UDP glucuronosyltransferase 1 family, polypeptide A6A 1.51 5.23 3.44
A_51_P163578 NM_172881 Ugt2b35 UDP glucuronosyltransferase 2 family, polypeptide B35 2.26 7.66 4.79
A_55_P1967350 NM_172881 Ugt2b35 UDP glucuronosyltransferase 2 family, polypeptide B35 2.69 7.69 5.11
Inﬂammation
A_55_P2016462 NM_021274 Cxcl10 Chemokine (C-X-C motif) ligand 10 2.55 1.67 1.29
Cell cycle arrest/cell death
A_55_P2145804 NM_026531 Aen Apoptosis enhancing nuclease 2.46 1.04 0.82
A_55_P2141860 NM_026531 Aen Apoptosis enhancing nuclease 2.34 1.02 0.81
A_55_P2002849 NM_175178 Aifm3 Apoptosis-inducing factor, mitochondrion-associated 3 −1.62 3.23 2.35
A_55_P2137406 NM_007527 Bax BCL2-associated X protein 1.73 2.45 1.84
A_51_P117794 NM_007546 Bik BCL2-interacting killer −1.68 5.20 3.43
A_55_P2029106 NM_138313 Bmf BCL2 modifying factor −2.30 6.34 4.08
A_51_P363947 NM_007669 Cdkn1a/p21 Cyclin-dependent kinase inhibitor 1a (p21) 4.64 2.16 1.31
A_55_P1969131 NM_178373 Cidec Cell death-inducing DFFA-like effector c 3.08 4.51 3.08
A_52_P311853 NM_030143 Ddit4l DNA-damage-inducible transcript 4-like 2.45 4.31 2.28
A_51_P336385 NM_175551 Dido1 Death inducer-obliterator 1 1.63 3.15 2.30
A_51_P189361 NM_027950 Osgin1 Oxidative stress induced growth inhibitor 1 2.38 3.62 2.58
A_55_P2027836 NM_020275 Tnfrsf10b/DR5 Tumor necrosis factor receptor superfamily, 10b/death receptor 5 1.92 2.33 1.76
A_55_P2027879 NM_172571 Fbf1 Fas (TNFRSF6) binding factor 1 2.28 3.72 2.64
Both (cell cycle arrest/cell death and cell survival/growth)
A_52_P452689 NM_007498 Atf3 Activating transcription factor 3 2.47 3.87 2.64
A_51_P502614 NM_026268 Dusp6 Dual speciﬁcity phosphatase 6 2.59 2.61 1.95
A_51_P263246 NM_008748 Dusp8 Dual speciﬁcity phosphatase 8 1.94 2.57 1.93
A_55_P2158990 NM_010591 Jun/c-Jun Jun oncogene 4.16 2.69 1.69
Cell survival/growth
A_55_P1979728 NM_009716 Atf4 Activating transcription factor 4 1.58 2.66 1.98
A_55_P1983773 NM_001012273 Birc5/survivin Baculoviral IAP repeat-containing 5/survivin 1.54⁎ 6.32 3.94
A_66_P111562 NM_007631 Ccnd1 Cyclin D1 1.53
A_52_P612803 NM_009831 Ccng1 Cyclin G1 2.00 1.63 0.48
(continued on next page)
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Table 2 (continued)
Probe ID GenBank
accession
Gene symbol Gene name Fold change
(8 mg/kg furan)
BMD
(mg/kg bw)
BMDL
(mg/kg bw)
A_51_P372550 NM_026770 Cgref1 Cell growth regulator with EF hand domain 1 1.65 4.14 2.88
A_52_P296913 NM_031396 Cnnm1 Cyclin M1 1.61 7.77 4.94
A_55_P1976127 NM_007900 Ect2 Ect2 oncogene 1.51 5.91 3.76
A_52_P237077 NM_007956 Esr1/ER1α Estrogen receptor 1 (alpha) 1.52 1.06
A_52_P235347 NM_020013 Fgf21 Fibroblast growth factor 21 3.25 7.63 5.23
A_55_P1960735 NM_011819 Gdf15 Growth differentiation factor 15 4.13 1.97 1.51
A_51_P220806 NM_008110 Gdf9 Growth differentiation factor 9 3.14 4.72 2.94
A_51_P447545 NM_008341 Igfbp1 Insulin-like growth factor binding protein 1 1.86 7.88 4.93
A_51_P260300 NM_010547 Ikbkg/NEMO Inhibitor of kappab kinase gamma 1.80 4.05 2.83
A_55_P2050652 NM_001136067 Ikbkg/NEMO Inhibitor of kappab kinase gamma 1.76 2.78 2.06
A_52_P108346 NM_010849 Myc/c-Myc Myelocytomatosis oncogene 1.84 4.48 3.06
A_55_P2007470 NM_008808 Pdgfa Platelet derived growth factor, alpha 1.89 1.03 0.72
A_55_P2125588 NM_008808 Pdgfa Platelet derived growth factor, alpha 1.88 1.80 1.39
A_55_P2092909 NM_019713 Rassf1 Ras association (ralgds/AF-6) domain family member 1 1.66 1.91 1.47
A_51_P111164 NM_172612 Rnd1 Rho family gtpase 1 −1.59 5.70 3.59
A_51_P404377 NM_009708 Rnd2 Rho family gtpase 2 1.89 1.13 0.45
A_55_P2184009 NM_009708 Rnd2 Rho family gtpase 2 1.73 4.24 2.93
A_55_P2031045 NM_011489 Stat5b Signal transducer and activator of transcription 5B −1.51 3.93 2.76
A_55_P2068663 NM_019641 Stmn1 Stathmin 1 1.53 4.94 3.30
A_51_P131408 NM_013749 Tnfrsf12a/TweakR Tumor necrosis factor receptor superfamily,
12a/TNF related weak inducer of apoptosis receptor
2.54 3.70 2.35
A_55_P2116496 NM_011654 Tuba1b Tubulin, alpha 1B 1.65 3.86 2.72
A_55_P2108837 NM_009448 Tuba1c Tubulin, alpha 1C 2.40 1.42 0.54
A_55_P2064547 BC022182 Tuba1c Tubulin, alpha 1C 2.36 1.53 0.55
A_52_P676271 NM_009447 Tuba4a Tubulin, alpha 4A 1.71 6.35 3.95
A_51_P490023 NM_009450 Tubb2a Tubulin, beta 2A 4.30 2.69 2.00
A_55_P2077783 NR_003964 Tubb2a-ps2 Tubulin, beta 2a, pseudogene 2 2.48 2.76 2.05
A_55_P2153292 NM_146116 Tubb2c Tubulin, beta 2C 2.86 1.41 1.10
A_55_P1959703 XM_001473123 Tubb2c-ps1 Tubulin, beta 2c, pseudogene 1 2.71 2.02 1.54
A_51_P421140 NM_026473 Tubb6 Tubulin, beta 6 1.71 1.96 1.51
⁎ P = 0.0776.
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others to support this hypothesis. We propose a molecular mecha-
nism for furan that accounts for furan-induced increases in liver cy-
totoxicity, inﬂammation and proliferation, leading to tumors, and is
anchored in the furan, Cyp2E1, liver regeneration, and spontaneous
or chemically induced HCC literature. Brieﬂy, the molecular initiat-
ing event is furan metabolism by CYP2E1. The resultant production
of BDA and ROS brings about changes in the cell that trigger cytotox-
icity and oxidative stress, which leads to inﬂammation. Regenerative
proliferation follows liver injury; however, when paired with chron-
ic elevation of NRF2 oxidative stress response and chronic inﬂamma-
tion, a transition point is created that tips the balances toward
sustained cellular proliferation. Tumorigenicity occurs when the
dose of furan results in a level of BDA and ROS production that
exceeds the rate at which the cell can neutralize them, thereby re-
quiring chronic elevation of these (normally protective) cellular
pathways. The result is sustained and dysregulated cellular prolifer-
ation that ultimately leads to cancer (Figs. 3 and 4).
In the larger context of spontaneous and chemically-induced
liver cancer, many potential molecules and signaling pathways
are hypothesized to be responsible for carcinogenic transforma-
tion during chronic liver injury. Prominent candidates, that are
also implicated in the present study, include tumor necrosis factor
alpha (TNF-alpha, which is a cytokine), c-Jun NH2-terminal kinase
1 (JNK1, which is a SAPK), and nuclear factor kappa B (NF-κB) and
c-Jun proto-oncogene/activator protein 1 (c-Jun/AP-1), which are
transcription factors. Indeed, previous studies of liver regenera-
tion have also identiﬁed TNF-alpha, JNK1, c-Jun and NF-κB as re-
quired for liver regeneration. In this study we obtained support
for their involvement, as well as many other gene products and
pathways including death receptor 5 (DR5), NRF2 oxidative stress
response, extracellular signal-regulated kinase (ERK) signaling,
and c-Myc and Statmin1 oncogenes in the development of HCC
and HCA in sub-chronically exposed mouse liver. All of these are
thoroughly explored below.Furan metabolism to BDA by CYP2E1 has been reported to produce
ROS and deplete GSH (Carfagna et al., 1993; Gonzalez, 2005; Lu and
Cederbaum, 2008). We thus examined our transcriptomic data for evi-
dence of induction of the oxidative stress response. First, we noted
that ROS and hydrogen peroxide were predicted upstream regulators.
Second, ROS producing CYP2E1 ligands (APAP, CT, and EtOH) were
also predicted to be activated (Fig. 3A), which indicates that the down-
stream effects of their metabolism are likely comparable to those of
furan. In addition,meta-analysis of gene expression data shows similar-
ity in furan-induced changes in genes expression to those induced by
hydrogen peroxide, CT and APAP (Fig. 2; Suppl. Table S6). Third, Enrich-
ment of the Glutathione Metabolism pathway (Fig. 3A) and increased
expression of relevant genes including glutamate-cysteine ligase, cata-
lytic subunit (Gclc) and glutathione-s-transferases (Gsta1 was the
most highly up-regulated gene; Table 2), all indicated that ROS produc-
tion, and GSH synthesis and depletion are occurring. Finally, the most
important indication of oxidative stress was the enrichment of the
Nrf2 Oxidative Stress Response pathway and prediction of Nrf2 activation
(Fig. 3). ROS can directly modify protein activity by oxidizing
disulfhydryl (R-(SH)2) groups on redox-sensitive proteins to disulﬁdes
(R-S2). A canonical example of this is the oxidation of Kelch-like ECH
protein 1 (KEAP1), which can only bind to and block Nrf2 in its reduced
form. Reduced KEAP1 holds Nrf2 in the cytoplasm with the Cullin-3
(CUL3) ubiquitin ligase, which targets Nrf2 for proteosomal degrada-
tion. When KEAP1 is oxidized, Nrf2 enters the nucleus and alters gene
expression of anti-oxidant and metabolic genes. We see up-regulation
of a plethora of downstream genes committed to redox homeostasis
and xenobiotic metabolism (Table 2). Therefore our toxicogenomics
data clearly support that hepatic, ROS-associated toxicity occurs in the
mouse model following exposure to furan.
Clearing ROS from the cell is a top priority as, in addition to modify-
ing protein function by redox, ROS can damage cellularmacromolecules
(such as DNA). This damage, when severe, leads to cellular necrosis.
Two cellular systems for neutralizing ROS are thioredoxin and
peroxiredoxin, which are involved in redox repair of oxidized cellular
Non Hepato-
carcinogens
Hepatocarcinogens
Non-Hepatocarcinogens
Hepatocarcinogens
Other (cancer, regeneration, inflammation)
Low  dose 
furan and 
Inflammation
High dose furan 
and liver cancer
Cyp2E1 ligands
Fig. 2. Cluster analysis comparing furan gene expression data with publically available datasets that reﬂect liver cancer (HCC), liver regeneration (LR), Cyp2E1 ligand-, and
hepatocarcinogen- and non-hepatocarcinogen-induced changes in gene expression in mouse liver. Datasets were downloaded from GEO, where G1 is GSE18858, G2 is GSE26538, G3 is
GSE35934, G4 is GSE20427, G5 is GSE4874, G6 is this study (GSE48644), and G7 is from another study conducted by our laboratory (Yauk et al., unpublished data; manuscript in prepa-
ration). Additional information for individual studies can be found in Suppl. Table S3.
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and AP-1 are both redox-sensitive proteins that require reduction
by thioredoxin for DNA binding (Arnér and Holmgren, 2000). Up-
regulation of the NRF2-target-genes thioredoxin reductase (Trxnd1)
and sulﬁredoxin (Srxn1) in our furan-exposed samples suggest that
both of these redox pathways are active (since TRXND1 and SRXN1 re-
duce oxidized thioredoxin and peroxiredoxin, respectively) (Fig. 3B).
NRF2 control over maintenance of cellular redox state is normally
cytoprotective; however, chronic elevation of NRF2-mediated gene ex-
pression has been shown to be detrimental and even to confer a survival
advantage to pre-cancer and cancer cells (Hayes and McMahon, 2006;Lau et al., 2008). We propose that this dual nature of NRF2 activation
might be a tipping point between normal cytotoxicity/regeneration cy-
cles and dysregulated ones. Moreover, chronic exposure to a ROS-
producing agent, such as furan, could tip the balance by causing chronic
KEAP1-inactivation/NRF2-activation and sustained maintenance of
downstream effects (Fig. 4).
Cytotoxicity and liver injury following chemical exposure occur ﬁrst
in furan's proposedMOA. Our transcriptomic data indicates that cellular
damage is occurring in our furan-exposed liver tissues. Meta-analysis of
gene expression produced similar changes as the following disease
states: Injury to Liver, Hepatic Fibrosis and Cirrhosis of the Liver
α α
α
α
β
κ
β
γ
ακ
κ
κ
βγ
A
B
Fig. 3. FuranMOA. (A) Summary of predicted upstream regulators (orange), enrichedmolecular pathways (green)with BMDLvalues indicated, and selecteddifferentially expressed genes
(bold text) for the 8 mg/kg bw dose group. (B) A more detailed image of the proposed redox switch and other molecular signals implicated in the furan MOA.
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Table 3
Margin of exposure (MoE) values for furan-induced molecular pathways and cancer endpoints. A MoE threshold of 1000 has been previously used for furan (IRIS, 2012). BMDLs for HCC
and HCAwere modeled using previously published data fromMoser et al. (2009) and NTP (1993) for female B6C3F1mice. BMDLmean for pathway data were calculated using transcrip-
tional data from this study in BMDExpress. Estimated human exposure levels were taken from Carthew et al. (2010).
NRF2 oxidative stress response pathway All-pathway-averagea Hepatocellular carcinoma Hepatocellular adenoma
(This study) (This study) Moser et al. (2009) NTP (1993) Moser et al. (2009) NTP (1993)
BMDL (μg/kg bw): 2250 2200 4218 5303 1567 923
Exposure estimates for child and adult (N2 years)
USA
Average (50%): 0.3 μg/kg-bw/day 7500 7333 14,060 17,677 5223 3077
High level (90%): 0.6 μg/kg-bw/day 3750 3667 7030 8838 2612 1538
Europe
Average (50%): 0.8 μg/kg-bw/day 2813 2750 5273 6629 1959 1154
High level (90%): 1.75 μg/kg-bw/day 1286 1257 2410 3030 895 527
Exposure estimates for infants (0–1 years)
USA
Average (50%): 0.4 μg/kg-bw/day 5625 5500 10,545 13,258 3918 2308
High level (90%): 1 μg/kg-bw/day 2250 2200 4218 5303 1567 923
Europe
Average (50%): 0.3 μg/kg-bw/day 7500 7333 14,060 17,677 5223 3077
High level (90%): 1 μg/kg-bw/day 2250 2200 4218 5303 1567 923
a Calculated using the average BMDL for all enriched pathways (enriched by 8 mg/kg bw furan, with at least 5 differentially expressed genes in each pathway).
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ptosis and Regulation of Programmed Cell Death (Suppl. Table S7). En-
richment of the Arachidonic Acid Metabolism pathway suggests that
Cyp2E1-catalyzed lipid peroxidation of polyunsaturated fatty acids like-
ly contributes to cytotoxicity through apoptosis (Chen et al., 1998). Up-
stream regulator prediction is a powerful tool that makes predictions
regarding molecule activation or inhibition based on downstream
gene expression. TNF-alpha was the only predicted upstream regulator
in response to 4 mg/kg bw furan and was among many predicted for
the 8 mg/kg bw dose group (Fig. 3). As such, we believe that TNF-
alpha must be among the earliest cytokines to respond to furan expo-
sure. TNF-alpha is a cytokine that signals through its receptor, TNF re-
ceptor 1 (TNFR1). During EtOH metabolism by CYP2E1, oxidative
stress promotes cell death by converting the (normally mitogenic)
TNF-alpha signal to a cytotoxic one and inducingmitochondrial perme-
ability transition (MPT) (Lu and Cederbaum, 2010; Pastorino and Hoek,
2000). MPT occurs when the MPT pores in the inner mitochondrial
membrane open, leading to membrane depolarization and uncoupling
that causes ATP depletion and eventually necrosis. MPT pore opening
can also result in mitochondrial swelling, leading to mitochondrial rup-
ture, cytochrome c release, caspase activation and apoptosis. MPT is
triggered by a variety of stimuli (e.g., various xenobiotics, Bax over-
expression, disulﬁde formation, increased mitochondrial Ca+, GSH de-
pletion, TNF-alpha signaling, andROS) and theoutcome (necrosis versus
apoptosis) is dependent on the biological context but is usually a com-
bination of the two (Jaeschke et al., 2002). Further evidence to support
the important role of the TNF superfamily (SF) in the cellular response
to furan is the enrichment of the Death Receptor (DR) pathway based
on up-regulation of Death Receptor 5 (DR5, aka Tnfrsf10b; Table 2),
which signals for cell death through TNFR-associated death domain
(TRADD), Fas-associated death domain (FADD), and the caspase
cascade.
SAPK phosphorylation cascades can also signal for MPT (Ashkenazi,
2002; Chu, 2013; Yuan and Kaplowitz, 2009). During APAPmetabolism
by CYP2E1, ROS production and GSH depletion lead to the activation of
apoptosis signaling kinase (ASK1). The ensuing ASK1, MAP2K4, JNK1
phosphorylation cascade leads to activation of Bcl-2-associated X pro-
tein (Bax), thereby causing hepatocyte cell death by MPT (Seki et al.,
2012). Interestingly, when the cell regains redox homeostasis, reduced
thioredoxin can block (ASK1) (Saitoh et al., 1998), and thereby inhibit
this cell death pathway (Fig. 3B). Enrichment of 14-3-3 signaling
(which has a ASK1, JNK1 component), prediction of activation of the
MAPK group and MAP2K4 (Fig. 3), enrichment of GO terms for protein
kinase activity and regulation of protein phosphorylation (Suppl.Table S7), and up-regulation of Bax and Dusp8 (a JNK-speciﬁc phospha-
tase) (Table 2, Fig. 3) all indicate that cytotoxicity from increased MPT
(as per Seki et al. (2012)) is relevant to furan. Another JNK1 substrate,
c-Jun, is a monomer of the heterodimeric transcription factor AP-1.
AP-1 has been described as a ‘double-edged sword’ in tumorigenesis be-
cause, depending on dimer composition and abundance, and the oxida-
tion state of the cell, it has been shown to have either oncogenic or
tumor suppressor capabilities (Eferl and Wagner, 2003; Hess et al.,
2004). c-Jun's contribution is typically understood to be pro-
proliferative; however, during periods of CYP2E1 activity and oxida-
tive stress, c-Jun and JNK1 are also known to be involved in hepato-
cyte cell death (Amir et al., 2012; Liu et al., 2002; Singh and Czaja,
2007; Singh et al., 2009). Indeed, loss of c-Jun has been shown to
prevent the CYP2E1-induced TNF-alpha switch from proliferative
to apoptotic signaling (Liu et al., 2002). The exact mechanisms by
which c-Jun functions during periods of oxidative stress compared
to normal cellular conditions are under investigation (Amir et al.,
2012; Karin and Shaulian, 2001). The combination of Cyp2E1 activa-
tion, ROS production and up-regulation of c-Jun and Dusp8 suggests
that the oxidative stress- and JNK1/c-Jun-mediated cell death mech-
anism (as per Amir et al. (2012)) is likely to also be relevant to furan.
Inﬂammation accompanies cell death and is triggered by pro-
inﬂammatory cytokines, released by Kupffer cells (liver-speciﬁc macro-
phages), and molecular signals released from dying cells (Nakagawa
and Maeda, 2012). Although acute inﬂammation is a normal part of
the innate immune response, chronic inﬂammation is thought to link
the cytotoxicity/regeneration MOA with HCC. This link is thought to
be the result of an increase in pro-proliferative cytokines, pro-
angiogenic factors and transcription factors with pro-proliferative tar-
get genes, particularly NF-κB (Berasain et al., 2009; DiDonato et al.,
2012; Karin, 2009). TNF-alpha can signal to activate NF-κB, which is im-
portant for initiation of both inﬂammation and hepatocyte proliferation
(Karin, 2006; Nakagawa and Maeda, 2012). NF-κB is a dimeric tran-
scription factor that is typically retained in the cytoplasmby its inhibitor
(IκB); however, up-regulation of IκB kinase (IκBk, which has three sub-
units: α, β, γ) allows NF-κB to enter the nucleus and modify gene ex-
pression. NF-κB activation in Kupffer cells leads to production of pro-
inﬂammatory cytokines, growth and survival signals, and angiogenic
factors (Karin, 2006). Kupffer cell-speciﬁc NF-κB inactivation (by IκBk-
γ knock-out) has been shown to reduce HCC tumor load, presumably
by reducing production of inﬂammatory signals (Berasain et al., 2009;
Maeda et al., 2005). NF-κB activation in hepatocytes leads to up-
regulation of cell-cycle and anti-apoptotic genes (Karin, 2006) and its
inhibition prevents tumor development and triggers apoptosis of
κB
Fig. 4. Schematics for the adaptive (upper panel) and adverse (lower panel) outcomes in response to non-carcinogenic (upper) and carcinogenic (lower) doses of furan. We propose that
NRF2 activation and inﬂammation could represent important tipping points in the MOA and that, when chronically activated, drive the cancer outcome.
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κB and JNK1 are known to antagonize one-another (Nakano et al., 2006;
Papa et al., 2004; Zhang and Chen, 2004). In addition, NF-κB itself is a
redox sensitive protein (Yuan and Kaplowitz, 2009). While the details
of this molecular cross-talk are still being investigated, it seems reason-
able to assume that if NF-κB activity were to get the ‘upper-hand’ it
could tip the balance away from JNK1-mediated cytotoxicity and to-
ward NF-κB-mediated inﬂammation and proliferation.
We expect that NF-κB is transcriptionally active in response to furan
since we see up-regulation of IκBk-γ (Table 2) and the NF-κBmonomer,
NF-κB1, is predicted to be activated (Fig. 3). In addition, our 1, 2 and
4 mg/kg dose groups each clustered most closely with an NF-κB-
mediated liver inﬂammation dataset (GSE20427; Fig. 2) and our
8 mg/kg bw dose group is correlated with the ‘Inﬂammatory Disease
of the Liver and Inﬂammatory Disorder’ phenotypes (Suppl. Table S5).
These data are consistent with the notion that NF-κB-mediated inﬂam-
mation in pre-cancer cells is an important part of setting the stage for
malignant transformation in furan exposed liver (but may not be sufﬁ-
cient for transformation on its own since 1 and 2 mg/kg bw doses furan
do not cause HCC).We observed up-regulation of the pro-inﬂammatory
chemokine C-X-C motif ligand (Cxcl10; Table 2), and prediction of acti-
vation of other cytokines (IL-1a, IL-1b, IL-6, IL-8, TNFSF11, TNF-alpha,
CXCL12, CCL5, IFN-γ) and of Triggered Receptor Expressed on Myeloid
Cells 1 (TREM1) (Fig. 3A). Kupffer cell expression of TREM1 has been
shown to be required for HCC development; further, loss of TREM1 re-
sults in down-regulation of transcription of pro-inﬂammatory and
pro-proliferative cytokines (IL-6, IL-b1, TNF-alpha, CCL2 and CXCL10)
and loss of activation of ERk1/2, JNK and NF-κB, ultimately preventing
malignant transformation (Wu et al., 2012). Our data support the idea
that inﬂammation precedes and facilitates carcinogenic transformation
in chemically induced HCC. These ﬁndings are consistent with previous
studies that have demonstrated the chronic inﬂammation phenotype in
furan-exposed mice and rats (Moser et al., 2009; NTP, 1993).
Regenerative proliferation is the penultimate stage to tumor forma-
tion in the furanMOA. Molecular mechanisms that underlie hepatocyte
proliferation have been studied using liver development, liver regener-
ation and spontaneous HCC models. NF-κB and c-Jun are both requiredfor liver development. Loss of NF-κB (by knock-out of IκBk-β or IκBk-γ)
is embryonic lethal because of extensive hepatocyte apoptosis and liver
degeneration (Li et al., 1999; Rudolph et al., 2000). c-Jun-null mice are
also embryonic lethal as a result of impaired liver and heart develop-
ment (Behrens et al., 2002; Eferl et al., 1999; Jochum et al., 2001).
Liver regeneration has been extensively studied in animals following
two-thirds partial hepatectomy (PH). Both NF-κB and c-Jun are not nor-
mally expressed/activated in adult liver, but are up-regulated following
PH in a TNF-alpha/TNFR1-dependent manner, and are required for he-
patic regeneration (Alcorn et al., 1990; Chaisson et al., 2002; Cressman
et al., 1994; Diehl et al., 1994; FitzGerald et al., 1995; Hilberg et al.,
1993; Yamada et al., 1997). Rats lackingNF-κB display impaired liver re-
generation due to hepatocyte apoptosis (Schrum et al., 2000) and mice
lacking AP-1 also show impaired liver regeneration, often leading to
death (Behrens et al., 2002). Similarly, in HCC TNF-alpha signals activa-
tion of both c-Jun/AP-1 andNF-κB,whichup-regulate expression of pro-
survival and pro-proliferation genes. IncreasedNF-κB expression inHCC
cells is important for the transition from liver injury and inﬂammation
to cancer (Karin, 2009; Luedde and Schwabe, 2011) and for HCC cell
growth (Pikarsky et al., 2004; Wang et al., 2003). Recently, up-
regulation of c-Jun gene expression in the early stages of liver cancer
has been shown to be required for HCC initiation and development
(Min et al., 2012). Both c-Jun and NF-κB have been proposed as molec-
ular targets for liver tumor prevention (Young et al., 2003).
Meta-analysis of our transcriptomic data demonstrates similarity in
gene expression changes produced by 8 mg/kg bw furan to those gen-
erated during liver regeneration, hepatocellular dysplasia, and liver can-
cer (Suppl. Table S5). Our 8 mg/kg bw dose group clustered most
closely with the spontaneous HCC and liver regeneration datasets
(Fig. 2). This is remarkable since our exposure was sub-chronic (there-
fore cells had presumably not yet undergone malignant transforma-
tion). We observed up-regulation of growth factors (Pdgf and Gdf9/15;
Table 2) and prediction of activation of others (VEGF, HGF, IGF1, EGF,
FGF, BMP2, BMP6; Fig. 3A) in response to furan. Growth factors are se-
creted proteins that bind their tyrosine receptor kinase and relay signals
through the cell via extracellular signal-regulated kinases (ERKs). The
MAPK phosphorylation cascade follows the order of RAS (GTPase),
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predicted upstream activators as is the MAPK/ERK Signaling pathway
(Fig. 3). ERKs were ﬁrst identiﬁed on the basis of being required for
the G1/S transition (Meloche and Pouyssegur, 2007) and are known to
activate at least 160 substrates (Min et al., 2011), which go on to alter
target gene expression. One target gene is dual-speciﬁc phosphatase 6
(Dusp6), which is up-regulated in response to furan (Table 2) and
feeds back to reset the pathway by dephosphorylating ERK1/2. During
periods of chronic oxidative stress, the ERK1/2 pathway is protective
against hepatocyte death (Singh and Czaja, 2007); this could be due to
the fact that DUSPs are oxidation-inactivated (Patterson et al., 2009).
We suggest that ERK signaling is responsible for promoting hepatic cel-
lular proliferation during liver regeneration.
In our samples, ERK signaling might promote cellular proliferation
via activation of protein substrates including: c-Jun/AP-1, c-Myc, and
Stathmin1. c-Jun has been shown to promote HCC by preventing hepa-
tocyte apoptosis through inhibition of p53 tumor suppressor (Eferl
et al., 2003) and SIRT6 (Sirtuin-6; a stress-responsive deacetylase). For
the latter, c-Jun blocks up-regulation of Sirt6, which results in increased
levels of Survivin (aka: Birc5) thereby blocking apoptosis (Min et al.,
2012). Survivin is marginally up-regulated by 8 mg/kg bw furan. Two
other AP-1monomerswere up-regulated by furan: activating transcrip-
tion factors 3 and 4 (Atf3/4; Table 2). ATF3 is up-regulated during the
stress response (Hai et al., 1999) and has been implicated in oncogene-
sis when bound to c-Jun (Thompson et al., 2009). ATF4 is up-regulated
in cancer and is known to regulate genes involved in oxidative stress re-
sponse, differentiation, metastasis and angiogenesis (Ameri and Harris,
2008). C-Myc oncogene is a transcription factor that is associated with
many cancers (Dang, 2012) and has been shown to contribute to HCC
progression during chronic EtOH exposure and CYP2E1 activation
(Tsuchishima et al., 2013) and to up-regulateNrf2 expression during tu-
morigenesis (Denicola et al., 2011). Finally, the Breast Cancer Regulation
by Stathmin1 pathway is enriched in both the 4 and 8 mg/kg bw furan
dose groups (Fig. 3A). Stathmin1 (Stmn1; aka Oncoprotein18, Op18)
is amicrotubule remodelingprotein that is not actually speciﬁc to breast
tissue/breast cancer (Stmn1 and Tubs are up-regulated by furan;
Table 2). Indeed, it has been shown to be involved in both liver regener-
ation (Okazaki et al., 1993; Rowlands et al., 1995) and HCC. Up-
regulation of Stathmin1 in HCC is correlated with poor prognosis and
tumor reoccurrence (Hsieh et al., 2010; Yuan et al., 2006). Silencing of
Stathmin1 in an HCC cell line (HCCLM3) suppressed proliferation, in-
duced apoptosis and impaired metastasis (Gan et al., 2010). ERKs likely
direct hepatic cellular proliferation via activation of other substrates as
well; however we believe that c-Jun, c-Myc, and Stathmin1 likely play
important roles during this process.
Taken together, we propose that all of the above molecules and
pathways (summarized in Fig. 3) are important contributors to furan-
induced regenerative proliferation leading to HCC. We also acknowl-
edge that, in order for HCA and HCC to develop, genomic damage
must occur.We propose that furan-induced genomic damage occurs in-
directly as a by-product of its metabolism (particularly the oxidative
stress and cytotoxicity aspects of the MOA). This hypothesis is based
on our observed induction of oxidative stress responses in combination
with themixed genotoxicity ﬁndings (discussed in the introduction; oc-
curring at high doses). In support of the occurrence of DNA damage at
high doses, we saw enrichment of the p53 Signaling pathway in
response to 8 mg/kg bw furan (but not 4 mg/kg bw). This pathway en-
richment was due to the up-regulation of the following genes: Cdkn1a,
Cyclin G1, Bax, DR5, and Teap1 (p53 inducible nuclear protein
1), which are all downstream targets of p53 that are suggestive of
DNA damage response.
In addition to applying our transcriptomics data to derive MOA in-
formation for furan, another objective of this work was to demonstrate
the practical application of toxicogenomics in quantitative risk assess-
ment.We accomplished this by calculatingBMDandMoE values for api-
cal and transcriptional endpoints since demonstration of a strongcorrelation between transcriptomic and apical endpoints will facilitate
the implementation of toxicogenomics in routine risk assessments
(Thomas et al., 2011). Strikingly, the majority of the transcriptional
BMD modeling that was conducted placed most values near to the ex-
pected 2–4 mg/kg bw POD range (Table 2, Fig. 3A, Suppl. Tables S3
and S7) as did modeling of HCC and HCA cancer endpoints reported
by Moser et al. (2009) and the NTP (1993) (Table 1). It is worth not-
ing that, while the transcriptional BMD/BMDL values were often
modeled using genes that had fold changes of less than ±2.0, the
most signiﬁcantly enriched pathways and functions tended to also
contain genes with larger fold changes. In addition, the magnitude
of the fold change of the individual probes did not appear to impact
the magnitude of the BMD/BMDL values (Table 2). Modeling of
previously-studied cytotoxicity and proliferation apical endpoints
showed more variability. BMD values calculated from apical data
for male and female B6C3F1 mice published by Gill et al. (2011)
were often below the 2 mg/kg bw cancer threshold and resembled
their NOAEL value (0.12 mg/kg bw) for furan. Alternatively, BMD
values calculated using apical data published in the NTP's (1993) ro-
dent cancer bioassay were much higher than the 2–4 mg/kg bw
range. The most sensitive cytotoxicity apical endpoint was hepato-
cyte apoptosis in the caudate lode (BMDL: 0.11 mg/kg bw), and
the most sensitive proliferation apical endpoint was hepatocyte ba-
sophilia (BMDL: 0.30 mg/kg bw) (Table 1). Both of these underesti-
mate the known cancer POD. The BMDLs for liver cancer more
closely approximated cancer POD with the HCA and HCC BMDLs
equal to 0.92 and 1.57 mg/kg bw, respectively (Table 1). Transcrip-
tional (pathway) BMDLs were within the same range of the cancer
BMDLs (1.50–4.40 mg/kg bw), with an average pathway BMDL of
2.20 mg/kg bw. The two pathways that we believe are very impor-
tant to the furan MOA, NRF2 Oxidative Stress Response and ERK/
MAPK Signaling, have very similar mean BMDLs of 2.25 and
2.62 mg/kg bw, respectively (Fig. 3). Strikingly, after only a three
week exposure, both the individual and the all-pathway-average
BMDL values perfectly reﬂect the 2–4 mg/kg bw cancer POD range.
We used the cancer and pathway BMDL values to estimate human
health risk using MoE values. Pathway MoE values were calculated
using either the NRF2 Oxidative Stress Response Pathway BMDL, or
the all-pathway-average BMDL. Pathway and HCA MoEs calculated
for transcriptional or apical endpoints were generally equivalent
(Table 3). While it is still early days and this work should be repeated
using other chemicals,we feel that this concordance between individual
and all-pathway-average BMDL (and therefore MoE) is an interesting
and important observation and tentatively suggest that an all-
pathway-average MoE might be a useful screening tool for initial esti-
mation of chemical risk.
In summary, using the MOA and the risk assessment information
gathered in this study we assembled a simpliﬁed adverse outcome
pathway for furan (Fig. 4). We believe that chronic exposure to
N2 mg/kg bw furan hijacks the normal response to manageable levels
of oxidative stress-induced damage thereby tipping the balances in
favor of chronic regenerative proliferation. The molecular initiating
event is Cyp2E1 ligand binding and furan metabolism to produce ROS.
The key events that follow are: (1) cytotoxicity, (2) activation of the
NRF2 oxidative stress response, (3) inﬂammation, and (4) regenerative
proliferation, where (2) and (3) represent tipping points between the
adaptive and the adverse outcomes. There is a large body of literature
supporting the idea that chronic NRF2 activation is carcinogenic, and it
is known that the POD for furan is between 2 and 4 mg/kg bw. There-
fore, we propose that the NRF2 oxidative stress response pathway
BMDL (2.25 mg/kg bw) would denote the best transcriptional bench-
mark dose for the POD between the adaptive and adverse responses
to furan. Above this dose the cytoprotective and defensive roles of
NRF2 are hijacked in premalignant and malignant cells to confer a sur-
vival advantage, and this is exacerbated by chronic inﬂammation
and up-regulation of other oncogenes (including c-Jun, c-Myc and
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al experiments, we feel that it provides realistic ﬁrst insight into how
furan causes cancer. We believe that our toxicogenomic approach is il-
lustrative of how gene expression data can provide MOA information
for indirectly acting and non-genotoxic carcinogens that is reﬂective of
apical cancer data. In addition, we believe that the consistency between
apical and genomic data demonstrates the utility of this approach for
the investigation of other non-genotoxic carcinogens that do not have
apical or two-year rodent bioassay data associated with them.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2013.10.019.
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